New direction for Galapagos. See MedNous

See MedNous for report on AstraZeneca Q3 results.

#Roche says gantenerumab, a candidate antibody for Alzheimer's disease, failed to slow disease progression. The level of beta-amyloid removal was also lower than expected. see MedNous

The Nov-Dec edition of MedNous is now out with articles on climate change and infectious disease, EMA draft guidance on real-world data, and oncology drug approvals. Contact [email protected].

#AstraZeneca to acquire Neogene Therapeutics, gaining access to T cell receptor therapies with potential for treating solid tumours. see MedNous

Experimental Moderna mRNA vaccine generated positive data in combination with Keytruda in melanoma patients at risk of relapse. MedNous

#lecanemab given accelerated approval by FDA for patients with Alzheimer's disease. see MedNous

The January 2023 edition of MedNous is now out featuring reviews of Covid-19 vaccines and therapies and 2022 data on oncology drug approvals. For further information write to [email protected].

#Sandoz to acquire antifungal agent from Astellas ahead of its launch as an independent Swiss company. See MedNous.

GLP-1 drug sales lifted group revenue and profit at Novo Nordisk in 2022. see MedNous.

#Sanofi announces the departure of John Reed, global head of R&D, and the appointment of interim successor Dietmar Berger. see MedNous

The February edition of MedNous is now available with a review article on Alzheimer's disease, the R&D strategy of a cohort of European mid-sized pharma companies and the 2022 WHO report on TB. For more information write to [email protected].

Year of change at Galapagos. see MedNous.

#SiliconValleyBank shuttered; new bank set up by the FDIC. see MedNous

The March edition of MedNous is now available to subscribers. It features original research for type 2 diabetes, a review of the late-stage oncology drug pipeline and an interview with #Adrenomed on septic shock. For further information, write to [email protected].

Alentis Therapeutics completes Series C financing of $105 mln to develop anti-claudin-1 antibodies, supported by Jeito and Novo Holdings. see MedNous

The April edition of MedNous is now out with articles on HIV vaccine research, the development of a new antibacterial by Destiny Pharma and a discussion of p38 MAPK inhibition by Matthew Wright at Kinarus. For a complimentary copy, write to [email protected].

The May issue of MedNous is now out featuring a review of proposed EU pharma legislation, new statistics on oncology drug development timelines and an interview with the radiopharmaceutical company Ariceum Therapeutics. For a complimentary copy write to [email protected].

Write to [email protected] for a complimentary copy of the June edition of MedNous with articles on a preclinical project for Alzheimer's disease, a review of ASCO 2023 and an exclusive report on biotech incubation in the UK.

The Jul-Aug 2023 edition of MedNous with articles on the new EU patent and the use of real-world evidence in regulatory decision making is now out. For further information write to [email protected].